Plasmodium yoelii macrophage migration inhibitory factor is necessary for efficient liver-stage development

Infection and Immunity

Volumn 80, Issue 4, 2012, Pages 1399-1407

  Miller, Jessica L ^a   Harupa, Anke ^a   Kappe, Stefan H I ^a,b   Mikolajczak, Sebastian A ^a  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; PROTOZOAL PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GROWTH RETARDATION; IN VIVO STUDY; LIFE CYCLE; LIVER CELL; LIVER STAGE DEVELOPMENT; MOSQUITO; MOUSE; NONHUMAN; PARASITE DEVELOPMENT; PARASITEMIA; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND; SPOROZOITE; ANIMAL; ANOPHELES; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; CELL STRAIN HEPG2; GENE INACTIVATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; LIVER; MALARIA; METABOLISM; PARASITOLOGY; PATHOGENICITY;

ANIMALS; ANOPHELES; CELL LINE; FEMALE; GENE KNOCKOUT TECHNIQUES; HEP G2 CELLS; HUMANS; LIVER; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALARIA; MICE; MICE, INBRED BALB C; PLASMODIUM YOELII; PROTOZOAN PROTEINS; SALIVARY GLANDS; SPOROZOITES;

EID: 84860791116     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05861-11     Document Type: Article

References (49)

1. Alam A, et al. 2011. Cysteine-3 and cysteine-4 are essential for the thioredoxin-like oxidoreductase and antioxidant activities of Plasmodium falciparum macrophage migration inhibitory factor. Free Radic. Biol. Med. 50:1659 -1668.
2. Augustijn KD, et al. 2007. Functional characterization of the Plasmodium falciparum and P. berghei homologues of macrophage migration inhibitory factor. Infect. Immun. 75:1116 -1128.
3. Awandare GA, et al. 2006. A macrophage migration inhibitory factor promoter polymorphism is associated with high-density parasitemia in children with malaria. Genes Immun. 7:568 -575.
4. Bacher M, et al. 1996. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. U. S. A. 93:7849 -7854.
5. Bernhagen J, Calandra T, Cerami A, Bucala R. 1994. Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. Trends Microbiol. 2:198 -201.
6. Bernhagen J, et al. 2007. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13:587-596.
7. Bozza M, et al. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189:341-346.
8. Calandra T. 2003. Macrophage migration inhibitory factor and host innate immune responses to microbes. Scand. J. Infect. Dis. 35:573-576.
9. Calandra T, Bernhagen J, Mitchell RA, Bucala R. 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179:1895-1902.
10. Conroy H, Mawhinney L, Donnelly SC. 2010. Inflammation and cancer: macrophage migration inhibitory factor (MIF)-the potential missing link. QJM 103:831- 836.
11. Cordery DV, et al. 2007. Characterization of a Plasmodium falciparum macrophage-migration inhibitory factor homologue. J. Infect. Dis. 195: 905-912.
12. de Mochel NS, et al. 2010. Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection. Hepatology 52:47-59.
13. Dobson SE, et al. 2009. The crystal structures of macrophage migration inhibitory factor from Plasmodium falciparum and Plasmodium berghei. Protein Sci. 18:2578 -2591.
14. Fingerle-Rowson G, et al. 2009. A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol. Cell. Biol. 29:1922-1932.
15. Grandvaux N, Soucy-Faulkner A, Fink K. 2007. Innate host defense: Nox and Duox on phox's tail. Biochimie 89:1113-1122.
16. Han C, et al. 2010. Plasma concentration of malaria parasite-derived macrophage migration inhibitory factor in uncomplicated malaria patients correlates with parasitemia and disease severity. Clin. Vaccine Immunol. 17:1524 -1532.
17. Hudson JD, et al. 1999. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190:1375-1382.
18. Imamura K, et al. 1996. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney. Biochem. Mol. Biol. Int. 40:1233-1242.
19. Jacobs-Lorena VY, Mikolajczak SA, Labaied M, Vaughan AM, Kappe SH. 2010. A dispensable Plasmodium locus for stable transgene expression. Mol. Biochem. Parasitol. 171:40-44.
20. Janse CJ, et al. 2006. High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol. Biochem. Parasitol. 145:60 -70.
21. Kamir D, et al. 2008. A Leishmania ortholog of macrophage migration inhibitory factor modulates host macrophage responses. J. Immunol. 180: 8250-8261.
22. Kanai T, et al. 2003. Macrophage-derived IL-18 targeting for the treatment of Crohn's disease. Curr. Drug Targets Inflamm. Allergy 2:131-136.
23. Kleemann R, et al. 2000. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408:211- 216.
24. Kleemann R, et al. 1998. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J. Mol. Biol. 280:85-102.
25. Klotz FW, et al. 1995. Co-localization of inducible-nitric oxide synthase and Plasmodium berghei in hepatocytes from rats immunized with irradiated sporozoites. J. Immunol. 154:3391-3395.
26. Labaied M, Camargo N, Kappe SH. 2007. Depletion of the Plasmodium berghei thrombospondin-related sporozoite protein reveals a role in host cell entry by sporozoites. Mol. Biochem. Parasitol. 153:158 -166.
27. Leng L, et al. 2003. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197:1467-1476.
28. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. 2002. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect. 4:449-460.
29. McDevitt MA, et al. 2006. A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. J. Exp. Med. 203:1185-1196.
30. Mikolajczak SA, Aly AS, Dumpit RF, Vaughan AM, Kappe SH. 2008. An efficient strategy for gene targeting and phenotypic assessment in the Plas-modium yoelii rodent malaria model. Mol. Biochem. Parasitol. 158:213- 216.
31. Mikolajczak SA, Kappe SH. 2006. A clash to conquer: the malaria parasite liver infection. Mol. Microbiol. 62:1499 -1506.
32. Mueller AK, et al. 2005. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc. Natl. Acad. Sci. U. S. A. 102:3022-3027.
33. Nemajerova A, Moll UM, Petrenko O, Fingerle-Rowson G. 2007. Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle 6:1030 -1034.
34. Noels H, Bernhagen J, Weber C. 2009. Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc. Med. 19:76-86.
35. Rennenberg A, et al. 2010. Exoerythrocytic Plasmodium parasites secrete a cysteine protease inhibitor involved in sporozoite invasion and capable of blocking cell death of host hepatocytes. PLoS Pathog. 6:e1000825.
36. Rosengren E, et al. 1996. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol. Med. 2:143-149.
37. Salminen A, Kaarniranta K. 2011. Control of p53 and NF-kappaB signaling by WIP1 and MIF: role in cellular senescence and organismal aging. Cell. Signal. 23:747-752.
38. Schober A, Bernhagen J, Weber C. 2008. Chemokine-like functions of MIF in atherosclerosis. J. Mol. Med. (Berlin) 86:761-770.
39. Shao D, et al. 2008. Detection of Plasmodium falciparum derived macrophage migration inhibitory factor homologue in the sera of malaria patients. Acta Trop. 106:9 -15.
40. Shao D, et al. 2010. Structural and functional comparison of MIF ortholog from Plasmodium yoelii with MIF from its rodent host. Mol. Immunol. 47:726 -737.
41. Shi X, et al. 2006. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25:595- 606.
42. Silvie O, et al. 2006. Expression of human CD81 differently affects host cell susceptibility to malaria sporozoites depending on the Plasmodium species. Cell. Microbiol. 8:1134 -1146.
43. Tarun AS, et al. 2007. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8_ T cells. J. Infect. Dis. 196:608-616.
44. Thiele M, Bernhagen J. 2005. Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid. Redox Signal. 7:1234 -1248.
45. Thorat S, Daly TM, Bergman LW, Burns JM, Jr. 2010. Elevated levels of the Plasmodium yoelii homologue of macrophage migration inhibitory factor attenuate blood-stage malaria. Infect. Immun. 78:5151-5162.
46. Vaughan AM, et al. 2009. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell. Microbiol. 11:506 -520.
47. Vermeire JJ, Cho Y, Lolis E, Bucala R, Cappello M. 2008. Orthologs of macrophage migration inhibitory factor from parasitic nematodes. Trends Parasitol. 24:355-363.
48. Weiss WR, Good MF, Hollingdale MR, Miller LH, Berzofsky JA. 1989. Genetic control of immunity to Plasmodium yoelii sporozoites. J. Immunol. 143:4263- 4266.
49. WHO. 2010. World malaria report. World Health Organization, Geneva, Switzerland.